

18th Joint event on

EUROPEAN OPHTHALMOLOGY CONGRESS & OCULAR PHARMACOLOGY

December 04-06, 2017 | Rome, Italy

Citicoline and neuroprotection in glaucoma disease

Giuseppe Fasolino
Catholic University, Italy

Citicoline has been employed as a therapeutic drug to treat some brain disorders including head injury, stroke and Parkinson's disease. In addition some clinical trials have shown that systemic treatment with citicoline may be effective against glaucoma. Citicoline, an intermediate product from the biosynthesis of phospholipids, is assumed to be transformed to cytidine monophosphate and phosphocoline by phosphodiesterases in the cell wall and taken up into neuronal cells. The protective effect of citicoline on damaged neurons is believed to accelerate biosynthesis of membrane phospholipids and stabilize intracellular circumstances after damage.

Biography

Giuseppe Fasolino has completed his medical degree from Catholic University in Roma in 1994. In 1999, he had done his Specialization in Ophthalmology at the University of Milan Policlinico S. Raffaele. His work experience is in San Raffaele Hospital in Milan as cataract surgeon from November 1999 until January 2001, Chief of retina department at the University Clinic Villa Tiberia in Rome from February 2001 until June 2007. From June 2007 he performs professional activities as chief of private centre Roma Retina Centre. He has numerous publications in international journals: Retina, Graefes, Arch, Seminars in Ophthalmology etc. He is also one of the author of monographs concerning the hereditary retinal degeneration. He always being the invited speaker at national and international scientific conferences (more than 300) regarding the diagnosis and treatment of the retina diseases

giuseppefas@tiscali.it

Notes: